(Q39312902)

10 September 2017

1 reference

title

The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress (English)

1 reference

10 September 2017

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28513879%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Seyed Mahdi Hassanian

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28513879%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Afsane Bahrami

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28513879%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Majid Khazaei

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28513879%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Soodabeh Shahidsales

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28513879%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Malihe Hasanzadeh

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28513879%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Mina Maftouh

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28513879%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Gordon A Ferns

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28513879%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

1 reference

17 May 2017

1 reference

Journal of Cellular Biochemistry

10 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28513879%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

119

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28513879%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28513879%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

213-222

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28513879%20AND%20SRC:MED&resulttype=core&format=json

Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab

10 June 2020

cites work

1 reference

Biomarker Analysis in CLEOPATRA: Searching for a Sensitive Prognostic Factor in Breast Cancer.

21 January 2018

1 reference

Role of Akt signaling in resistance to DNA-targeted therapy

21 January 2018

1 reference

Targeting the tumor microenvironment as a potential therapeutic approach in colorectal cancer: Rational and progress.

21 January 2018

1 reference

Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer

21 January 2018

1 reference

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

21 January 2018

1 reference

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

21 January 2018

1 reference

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population

21 January 2018

1 reference

The phosphoinositide 3-kinase pathway

21 January 2018

1 reference

Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer

21 January 2018

1 reference

A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.

21 January 2018

1 reference

Systemic Therapy of Advanced/Metastatic Breast Cancer - Current Evidence and Future Concepts

21 January 2018

1 reference

PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer

21 January 2018

1 reference

Dissecting the role of mTOR: lessons from mTOR inhibitors

21 January 2018

1 reference

Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer

21 January 2018

1 reference

Current approaches to the management of Her2-negative metastatic breast cancer

21 January 2018

1 reference

Defining the role of mTOR in cancer

21 January 2018

1 reference

Exploiting the PI3K/AKT pathway for cancer drug discovery

21 January 2018

1 reference

Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2

21 January 2018

1 reference

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

Targeting the PI3K-AKT-mTOR signaling network in cancer

21 January 2018

1 reference

Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells

21 January 2018

1 reference

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

21 January 2018

1 reference

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer

21 January 2018

1 reference

Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer

21 January 2018

1 reference

Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity

21 January 2018

1 reference

Everolimus: side effect profile and management of toxicities in breast cancer

21 January 2018

1 reference

Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?

21 January 2018

1 reference

Molecular portraits of human breast tumours

21 January 2018

1 reference

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial

21 January 2018

1 reference

Triple negative tumours: a critical review

21 January 2018

1 reference

Tenets of PTEN tumor suppression

21 January 2018

1 reference

Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer.

21 January 2018

1 reference

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

21 January 2018

1 reference

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

21 January 2018

1 reference

Targeting mammalian target of rapamycin (mTOR) for health and diseases.

21 January 2018

1 reference

Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibit

21 January 2018

1 reference

Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain

21 January 2018

1 reference

Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway

21 January 2018

1 reference

PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JCB.26136

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28513879%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference